R. Nahta

Oncology · 2004–2012

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom R. Nahta trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. H. Horlings
  2. M. Hung

Who trusts R. Nahta overall

  1. G. Valabrega
  2. W. Scheuer
  3. K. Imai
  4. F. Montemurro
  5. J. Baselga
  6. Rendong Yang
  7. Carlos L. Arteaga
  8. S. Swain
  9. T. Friess
  10. M. Aglietta

Papers from R. Nahta's perspective

Ordered by how strongly the researchers R. Nahta trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
  2. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
  3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  4. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
  5. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) (Cancer Research)
  6. The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (Cancer Research)
  7. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (New England Journal of Medicine)
  8. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (Cancer Research)
  9. Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
  10. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. (Journal of Clinical Oncology)

Their papers